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This paper develops hypotheses regarding the interactions among stress, immunity, and
chemical sensitivities and gives an overview of the questions and hypotheses generated by a
working group exploring the application of psychoneuroimmunology to chemical sensitivities.
Consideration is given to prospective longitudinal studies designed to find cases among at-risk
exposed populations. Relevant immune parameters to be measured longitudinally and in
challenge studies for patients with MCS are discussed. Immune system changes in response to
the chronic stress of having MCS and as primary responses to chemical exposure also are
considered. Environ Health Perspect 105(Suppl 2):527-529 (1997)
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Introduction
Psychoneuroimmunology is defined as the
study ofbehaviorally associated changes in
immunity and immunologically associated
changes in behavior that result from the
interaction among the nervous, endocrine,
and immune systems (1,2). The charge to
this working group was to develop experi-
mental protocols with which to investigate
multiple chemical sensitivity (MCS) from
the heretofore unconsidered perspective of
psychoneuroimmunology. Given that the
involvement of the immune system in
MCS is still an area of some controversy,
the impact ofpsychoneuroimmunological
processes on the onset, development, and
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dinical course ofMCS is problematic. Thus,
the group also considered a reasonable area
ofscientific inquiry to be the possible influ-
ences on immunity ofthe stress associated






During its deliberations, the group raised
the following six related sets of questions
whose answers could reveal a relationship
among behavioral stimuli, neural-immune
system interactions, and MCS.
In situations in which a sensitizing
chemical may be immunomodulatory,
do environmental cues temporally
associated with the sensitizing exposure
serve as conditioned stimuli (4)? Ifso,
can such cues, with or without sub-
threshold amounts of the chemical,
elicit a chemical sensitivity response?
Can the chemical sensitizer itself, pro-
vide both unconditioned and condi-
tioned stimuli?
* Are there significant immunological,
neuroendocrine, and psychosocial devi-
ations from normalcy shortly before, at
the time of, or consequent to, the
development ofMCS symptomatology?
Ifphysiological changes are noted con-
sequent to psychosocial changes, are
those psychosocial changes implicated
in the development of MCS? If so,
could psychological/behavioral inter-
vention be oftherapeutic value, at least
in some subset ofpatients (3)?
* What is the interval between the initiat-
ing event and the development ofearly
symptoms ofMCS? What is the inter-
val between the initial trigger and the
so-called increase in sensitivities to
diverse stimulants?
* Is the duration ofthese intervals related
to psychosocial factors (e.g., stress) or
to personality/sex/health status (e.g.,
allergic status, autoimmunity or auto-
immune predisposition) ofthe subject,
or the chemical nature ofthe initiator?
Do events perceived as stressful in the
recent or past history of the individual
play roles in the onset and/orprogression
ofMCS?
* What do chemical initiators of MCS
and initiators of MCS such as a car
accident or childbirth have in com-
mon? Which factor is more important
in the traumatic initiation: the exposure
to chemicals associated with the trau-
matic event, and/or the stressful experi-
ence associated with the event? Can a
stressor precipitate MCS in a chemi-
cally sensitized individual who is not
displaying overt symptoms of MCS at
the time ofstressor exposure?
* Why is there variability in the develop-
ment and severity ofMCS? Is there any
relationship between major histocom-
patibility complex phenotype and MCS?
Is there a detectable humoral or cellular
immune response to the initiatingchem-
ical? Is an immune response causal or
the result ofthe MCS process(es)?
Hypotheses
These and other questions raised during the
group discussions suggest the following two
related hypotheses linking psychoneuro-
immunology and MCS. The first hypothe-
sis states that at least in some patients, a
psychoneuroimmunological component is
correlationally or causally associated with
the development of MCS, including
reactions produced by immunological or
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behavioral mechanisms. The second
hypothesis states that the stress associated
with MCS as a chronic disabling disease
leads to an altered neuroendocrine immune
milieu which, in turn, is associated with
measurable changes in immune function
and associated incidence and severity of
immunologically related diseases (e.g.,
infectious disease, autoimmune disease,
cancer). Both of these hypotheses are
testable in prospective longitudinal studies
involving the following populations.
Study 1: Population exposed to a
chemical initiating event-for example, the
installation ofnew carpets (including glue)
in the workplace.
Study 2: Population exposed to a man-
made chemical spill.
Study 3: Population exposed to a
natural disaster such as an earthquake,
flood, or hurricane.
SubjectSelection
An assumption common to each study
population is that some percentage of the
individuals in each heterogeneous popula-
tion will within a predetermined period
(e.g., 1 year) develop MCS. These subjects
will comprise the first study group. A sec-
ond group will consist ofthose individuals
who have been exposed to the same stimuli
but do not develop MCS within the same
predetermined time period. To determine
whether individuals in this second group
exhibit any immunological consequences
of the exposure that might have a psy-
chosocial attribution, a group of demo-
graphically matched individuals that have
not been exposed could be studied. Given
the assumption that the cost ofperforming
these studies is ofno consequence, all sub-
jects in each study population will be eval-
uated, by health status, by a full battery of
immunological tests. Some examples of
immunologic assessments are serum
immunoglobulin levels (all isotypes); com-
plement levels; mitogen responses; TH1-
and TH2-derived cytokine levels; proin-
flammatory cytokine (e.g., IL-1, IL-6,
TNF-a) levels; soluble and cell-bound
cytokine receptors; natural killer (NK) cell
numbers and activity; substance P and
proinflammatory cytokines in nasal lavage;
quantitative cytokine mRNA; antibody
titers to volatile organic compounds
(VOCs); antibodies to a benign antigen or
flu vaccine (immunized during study); and
skin testing with standard recall antigens
and allergens. Psychometric instruments
will also be used to evaluate such factors as
stress, loneliness, coping, helplessness, and
suggestibility. The following are examples
ofpsychometric instruments: the Profile of
Mood States questionnaire; the Minnesota
Multiphasic Personality Inventory; the
Reaction Scheme Test; and the State and
Trait Anxiety Inventory. These procedures
will be done before and periodically after
(e.g., 1, 3, 6, 9, 12 months) the putative
initiating event. Variables to be considered
(and controlled for) as ways of separating
(stratifying) the subject population, include
but are not restricted to the typical demo-
graphic issues of age, sex, socioeconomic
status, and ethnicity. The hypothesis to be
tested is that: some psychosocial factor(s)
will distinguish individuals who develop
MCS from those who do not.
Total VOC concentration and selected
VOCs will be measured in the air and bio-
logical fluids (blood) of the subjects to
determine the actual exposure received in
study 1. Estimates of the exposures in
study 2 would rely on measurements in
biological fluid (blood or urine) ofthe sus-
pected compounds of exposure or their
metabolites. Consideration must be given
to the time interval between when the
exposure occurred and when the biological
sample was collected and the biological
half-life ofthe species measured.
Controlied ExposureStudies
There are multiple design problems
inherent in conducting clinical studies of
MCS patients under controlled exposure
conditions. These include selection ofthe
appropriate exposure conditions such as
routes ofdelivery, issues regarding blinding
or masking, and identification and utiliza-
tion of relevant response measures. With
respect to relevant response measures, most
MCS patients report acute symptoms that
occur within minutes to hours ofthe expo-
sure. The time course of this symptom-
exposure relationship makes mechanisms
involving neoantibody production highly
suspect and focuses attention on local
inflammatory responses; the production/
release ofproinflammatory cytokines such
as IL-1, IL-6, and TNF-a; the release of
acute phase proteins; and immediate
hypersensitivity reactions.
One design problem associated with
these studies is selecting the time after the
initiating event when individuals who
develop MCS in the study populations
should undergo controlled exposure test-
ing. This could be a fixed time (e.g., 1
year) after the initiating event or it could
be a predetermined time after development
ofMCS that is independent ofthe time of
the initiating event. If the latter time is
used, then selection ofthe individual from
the exposed group who does not develop
MCS at the time ofa controlled exposure
becomes a problem (i.e., that individual
could, in principle, still develop MCS after
the predetermined time).
There are several approaches to per-
forming controlled exposure studies that
may be applicable to the MCS question.
Perhaps the most valid approach to con-
trolled subject testing is a double-blind
study design in which the subject is unable,
from usual sensory perceptions, to detect
the exposure condition. If the controlled
exposure is conducted within a longitudinal
study as described, it would be useful to
compare the psychosocial variables collected
at initiation ofthe studies for those subjects
with high and low hit rates for detecting
chemicals in subthreshold concentrations.
Although olfactory maskers were
successfully used in one study, the odors
and irritant effects ofvolatile organic chem-
icals make blinding extremely difficult. One
can consider using subthreshold exposure
levels where individual subject perceptual
(olfactory, sensory irritation) thresholds are
determined and exposure conditions are set
at some magnitude below this level. How-
ever, in considering the complexities and
controversies of MCS, such studies likely
would come under intense criticism ifper-
formed without allowing for the adapta-
tion/masking phenomena described by
MCS proponents. Another approach in
reevaluating the MCS phenomenon is to
utilize above-threshold exposures in an
attempt to identify physiological or bio-
chemical parameters that provide biologic
plausibility for the reported symptoms;
such workwould be exploratory. Using rec-
ognizable above-threshold exposures would
not be blinded and would not differentiate
between conditioning and other underlying
mechanisms. However, such an approach
possibly would provide a measure other
than symptoms that could then be exam-
ined further with regard to dose-response,
routes of exposure, and blinding. This
approach would require studying subjects
who report the symptoms ofinterest.
Response Measures
In addition to measuring symptoms of
MCS, preference should be given to mea-
sures that can be made during or in close
proximity to exposures. The measures
selected must have biologic plausibility for
the symptoms reported by the MCS
patients. Most MCS patients report acute
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symptoms that occur within minutes to
hours following an exposure. The time
course ofthis symptom-exposure relation-
ship makes mechanisms that involve
antibody production or cell-mediated
immunity highly suspect and focuses atten-
tion on local (e.g., nasal) inflammatory
responses and the local and systemic pro-
duction ofproinflammatory cytokines such
as IL-1, IL-6 and TNF-a measured pre-
and postexposure. Additional analyses of
endocrine activation (stress hormones such
as salivary cortisol) and autonomic nervous
system arousal (heart rate, skin conduc-
tance, pupilography, catecholamines)
before and after deliberate exposure should
also be conducted. In summary, the follow-
ing should be examined during or in close
proximity to challenges: systemic inflam-
matory markers (e.g., proinflammatory
cytokines) (relevant symptoms: fatigue,
arthralgias, myalgias); nasal inflammatory
markers-neuropeptides, proinflammatory
cytokines, histamine/tryptase, cells, albumin
(relevant symptoms: nasal symptoms);
autonomic nervous system-heart rate,
skin conductance, pupilography (relevant
symptoms: dizziness, palpitations, flushing,
cold extremities, anxiety); endocrine sys-
tem-stress hormones (e.g., salivary corti-
sol, prolactin); stress measures-heart rate,
respiratory rate, end-tidal CO2 (relevant
symptoms: anxiety, palpitations, dyspnea).
Psychoneuroimmunological
Consequences ofMCS
Regardless ofwhether there is a psycho-
neuroimmunological component to the
development of MCS, it is reasonable to
hypothesize that there are behavioral and
immunological consequences of MCS that
may be attributable to the stress of a
chronic disability (3). Thus, it might prove
useful to longitudinally follow individuals
who develop MCS and periodically moni-
tor their psychosocial status, immune func-
tion, and general health. An important
related question, at least from the perspec-
tive of the psychoneuroimmunologist, is
whether abnormalities in any ofthese para-
meters are associated, at least correlation-
ally, with an altered incidence ofmicrobial
diseases, autoimmune diseases, and cancer.
If so, perhaps appropriate psychosocial
interventions can be developed. In terms of
intervention, it would be informative to
determine the extent to which MCS
patients are consumers ofalternative (com-
plementary) medical therapies, and whether
such treatments have beneficial effects.
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